

Testing for Hepatitis C Virus (HCV)

Leading The Way In HCV Testing

LabCorp, and its specialty laboratory, Monogram Biosciences, offer a comprehensive menu for screening and treating patients with Hepatitis C (HCV). LabCorp was the first to develop valuable viral resistance testing for patients undergoing HCV treatment, the first in the US to offer FibroSure® liver status through serum testing, and is a national laboratory that utilizes an approved assay to confirm HCV infection that meets the screening guidelines established by the CDC. In addition to its leading technologies, LabCorp offers physicians the flexibility to choose HCV testing they feel is most appropriate for their patients, including cost-effective antibody-only screening, quantitative viral loads, a wide variety of assays to manage antiretroviral therapy, and customized testing options upon request.

HCV Screening

The CDC guidelines recommend an initial screen using an FDA-approved antibody test.¹ For any antibody results that are positive, the CDC recommends using an FDA-approved NAT — also called an HCV RNA test — to identify active HCV infection.¹ To further support the appropriate screening of all “at risk” patients for HCV infection, LabCorp will begin including a message on positive HCV antibody screen results that CDC guidelines recommend follow-up utilizing an approved NAT confirmation test.

LabCorp offers test **144050 – Hepatitis C Virus (HCV) Antibody With Reflex to Quantitative Real-time PCR** using FDA-approved antibody and NAT tests to aid in the initial screening and follow up of those who are indicated for HCV evaluation. Any specimens found to be positive using the antibody test will automatically be tested using a quantitative HCV RNA test that will confirm an active hepatitis infection. The quantitative assay will provide an accurate measurement of a patient’s viral load.²

HCV antibody testing and HCV RNA testing may also be ordered individually.

LabCorp offers test **140659 – Hepatitis C Virus (HCV) Antibody** to assess exposure to hepatitis C virus infection. All positive results reports will include a message that CDC guidelines recommend follow-up utilizing an approved NAT confirmation test.

LabCorp offers test **550070 – Hepatitis C Virus (HCV), Quantitative, Real-time PCR (Graphical)** and test **550080 - Hepatitis C Virus (HCV), Quantitative, Real-time PCR (Nongraphical)** to determine the number of international units (IU) of hepatitis C virus (HCV) RNA per milliliter of serum or plasma in known HCV-positive patients. These tests are approved for diagnosis of infection.²

LabCorp also offers a convenient HCV cascade test **144127 - Hepatitis C Virus (HCV) Antibody Cascade to Quantitative PCR and Genotyping** that reflexes a positive antibody test to quantitative PCR and then to genotyping when the viral load is > 1000 IU/mL.

Single-Source HCV Solution

LabCorp offers a comprehensive menu of HCV tests to aid in screening, diagnosis, staging, prognosis, and monitoring of patients with HCV, including antibody verification assays, genotyping (subtyping), HCV FibroSure® noninvasive liver assessment, quantitative viral load for monitoring, and resistance assays. Contact your sales representative for a full list of available assays.

LabCorp’s Hepatitis C Virus (HCV) Antibody With Reflex to HCV RNA, Quantitative Real-time PCR (144050), is appropriate for HCV screening and follow up in support of CDC recommendations.

References

- Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. *MMWR* 2012;61 (No RR-4):1-32.
- Roche Molecular Systems. *COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, Version 2.0*. Indianapolis, Ind: Roche Diagnostics; 2016.